Search results for " visceral"

showing 10 items of 68 documents

In vivo and in vitro cytokine profiles and mononuclear cell subsets in sicilian patients with active visceral leishmaniasis

1995

Sera from Sicilian patients with confirmed visceral leishmaniasis (Leishmania donovani infantum) were analysed at the moment of the diagnosis, during the course of the disease and after clinical recovery, for the concentration of IL-10, IFN-gamma, IL-4 and IL-2. The results show high concentrations of IL-10 and IFN-gamma in the sera at the beginning of infection that return to the normal range following successful chemotherapy. By contrast, PBMC stimulated in vitro with Ag and mitogen produced low levels of IL-10 and IFN-gamma when collected at the time of the diagnosis and normal levels when assayed after recovery. IL-2 was undetected in the sera and was significantly reduced in the supern…

MaleCD3medicine.medical_treatmentImmunologyAntigens ProtozoanBiochemistryPeripheral blood mononuclear cellAntigenIn vivomedicineAnimalsHumansImmunology and AllergyMacrophagePhytohemagglutininsSicilyMolecular BiologybiologyHematologymedicine.diseaseStimulation ChemicalRatsVisceral leishmaniasisCytokineCase-Control StudiesImmunologyDisease ProgressionLeukocytes Mononuclearbiology.proteinLeishmaniasis VisceralFemaleCD8Cytokine
researchProduct

Cut-off points of the visceral adiposity index (VAI) identifying a visceral adipose dysfunction associated with cardiometabolic risk in a Caucasian S…

2011

Abstract Background The Visceral Adiposity Index (VAI) is a sex-specific mathematical index, based on Waist Circumference (WC), Body Mass Index (BMI), triglycerides (TG) and HDL cholesterol (HDL) levels, indirectly expressing visceral adipose function and insulin sensitivity. Our aim was to find the optimal cut-off points of VAI identifying a visceral adipose dysfunction (VAD) associated with cardiometabolic risk in a Caucasian Sicilian population. Methods Medical check-up data of 1,764 Primary Care patients (PC patients) were retrospectively and cross-sectionally examined using a receiver-operating characteristic (ROC) curve to determine appropriate stratified-for-age cut-off of VAI, for t…

MaleCross-sectional studyEndocrinology Diabetes and MetabolismClinical BiochemistrySettore MED/13 - EndocrinologiaEndocrinologyReference ValuesRisk Factorscardiometabolic riskPrevalenceMyocardial infarctionSicilylcsh:RC620-627Aged 80 and overMetabolic Syndromeeducation.field_of_studyMiddle Agedlcsh:Nutritional diseases. Deficiency diseasesCardiovascular DiseasesCardiologyvisceral adipose dynsfunctionFemaleAdultmedicine.medical_specialtyWaistAdolescentPopulationVisceral adiposity index VAI Obesity cardiometabolic risk visceral adipose dynsfunctionClinical nutritionIntra-Abdominal FatWhite PeopleYoung AdultInternal medicineDiabetes mellitusmedicineHumansBody Weights and MeasuresObesitycardiovascular diseaseseducationAgedRetrospective StudiesBiochemistry medicalbusiness.industryResearchBiochemistry (medical)medicine.diseaseVAIEndocrinologyCross-Sectional StudiesDiabetes Mellitus Type 2Metabolic syndromebusinessBody mass indexLipids in Health and Disease
researchProduct

Pasireotide treatment reduces cardiometabolic risk in Cushing’s disease patients: an Italian, multicenter study

2018

Purpose: Patients with Cushing’s disease (CD) experience metabolic alterations leading to increased cardiovascular mortality. Recently, the visceral adiposity index (VAI) has been proposed as a marker of visceral adipose tissue dysfunction (ATD) and of the related cardiometabolic risk. We aimed to evaluate the impact of 12-month pasireotide treatment on cardiometabolic risk in CD patients. Methods: This is a multicentre, prospective, and observational study. Sixteen CD patients, referred to the Endocrine Units of the University Hospitals of Messina, Napoli, Padova, and Palermo (Italy), successfully treated with pasireotide for 12 month have been enrolled. In all patients, we assessed anthro…

MaleEndocrinology Diabetes and MetabolismCardiometabolic risk Cushing’s disease hypercortisolism pasireotide visceral adiposity indexLongitudinal StudieDisease030204 cardiovascular system & hematologySettore MED/13 - Endocrinologiachemistry.chemical_compound0302 clinical medicineEndocrinologyRisk FactorsMedicineLongitudinal StudiesProspective StudiesAdiposityFramingham Risk ScoreCushing’s diseaseCushing’s diseaseMiddle AgedPasireotideDiabetes and MetabolismHeart DiseaseItalyAtherosclerosiObesity AbdominalFemaleSomatostatinHumanAdultmedicine.medical_specialtyWaistHeart DiseasesHypercortisolism030209 endocrinology & metabolismIntra-Abdominal Fat03 medical and health sciencesMetabolic DiseasesInternal medicineDiabetes mellitusCardiometabolic risk; Cushing’s disease; Hypercortisolism; Pasireotide; Visceral adiposity index; Endocrinology Diabetes and Metabolism; EndocrinologyHumansPituitary ACTH Hypersecretionbusiness.industryRisk FactorCushing's diseaseAnthropometryAtherosclerosismedicine.diseasePasireotideCardiometabolic riskMetabolic DiseaseVisceral adiposity indexProspective StudiechemistryObservational studybusiness
researchProduct

Knowledge, stigma, health seeking behaviour and its determinants among patients with post kalaazar dermal leishmaniasis, Bihar, India

2018

Background Lesishmaniasis is a neglected tropical disease endemic in Bihar, India. Inappropriate health seeking behaviour of post kala-azar dermal leishmaniasis (PKDL) patients may increase the disease duration, severity and transmissibility. Simultaneously, lack of knowledge and perceived stigma may also increase the length of delay in receiving treatment. This ultimately effects the kala-azar elimination program. Methods A cross sectional study was conducted in 120 confirmed PKDL patients, aged 18 years and older. Data related to knowledge and health seeking behaviour was collected by a pre-tested questionnaire. EMIC stigma scale was used for assessing the perceived stigma. Patients were …

MaleHealth Knowledge Attitudes PracticePediatricsTime FactorsSocial stigmaCross-sectional studyHealth Care ProvidersHealth BehaviorSocial Stigmalcsh:MedicineDiseaseDisease VectorsPathology and Laboratory Medicine0302 clinical medicineInformed consentZoonosesMedicine and Health SciencesMedicinePublic and Occupational Health030212 general & internal medicineYoung adultlcsh:ScienceLeishmaniasisMultidisciplinaryMiddle AgedInfectious DiseasesLeishmaniasis VisceralFemaleBehavioral and Social Aspects of HealthResearch ArticleNeglected Tropical DiseasesAdultmedicine.medical_specialtyAdolescentPatients030231 tropical medicineAntiprotozoal AgentsIndiaLeishmaniasis CutaneousStigma (botany)DermatologySkin DiseasesYoung AdultKala-Azar03 medical and health sciencesSigns and SymptomsDiagnostic Medicineparasitic diseasesParasitic DiseasesHumansAgedProtozoan Infectionsbusiness.industrylcsh:RBiology and Life SciencesTropical diseasePatient Acceptance of Health CareTropical Diseasesmedicine.diseaseInsect VectorsSand FliesHealth CareSpecies InteractionsCross-Sectional StudiesLesionslcsh:QbusinessLeishmania donovaniPatient educationPLOS ONE
researchProduct

A 6 day course of liposomal amphotericin B in the treatment of infantile visceral leishmaniasis: the Italian experience

2004

Objectives To evaluate in a retrospective analysis the efficacy and safety of a 6 day course of liposomal amphotericin B (L-AmB) in infantile cases of Mediterranean visceral leishmaniasis (VL) diagnosed over a 10 year period in Italy. Patients and methods Patients included were diagnosed as having VL consecutively admitted from December 1992 to December 2001 at four main referral children's hospitals in Italy and treated with six intravenous doses of 3 mg/kg L-AmB given on days 1-5 and 10 (a total dose of 18 mg/kg). Demographic data, nutritional status, underlying diseases, clinical and laboratory findings, and therapy outcome were considered. Results A total of 164 HIV-negative children (m…

MaleMicrobiology (medical)medicine.medical_specialtyAdolescentFeverAntiprotozoal AgentsFluorescent Antibody TechniqueNutritional Statusitaly; leishmania infantum; therapyBone MarrowRecurrenceAmphotericin BInternal medicineAmphotericin BmedicineHumansPharmacology (medical)ChildAdverse effectleishmaniasisRetrospective StudiesPharmacologyDrug Carriersbiologybusiness.industryInfantRetrospective cohort studyLeishmaniasismedicine.diseasebiology.organism_classificationSurgeryRegimenTreatment OutcomeInfectious DiseasesVisceral leishmaniasisItalyEl NiñoChild PreschoolLiposomesLeishmaniasis VisceralFemaleLeishmania infantumbusinessmedicine.drug
researchProduct

Arginase activity in the blood of patients with visceral leishmaniasis and HIV infection.

2013

Background Visceral leishmaniasis is a parasitic disease associated with high mortality. The most important foci of visceral leishmaniasis in Ethiopia are in the Northwest and are predominantly associated with high rates of HIV co-infection. Co-infection of visceral leishmaniasis patients with HIV results in higher mortality, treatment failure and relapse. We have previously shown that arginase, an enzyme associated with immunosuppression, was increased in patients with visceral leishmaniasis and in HIV seropositive patients; further our results showed that high arginase activity is a marker of disease severity. Here, we tested the hypothesis that increased arginase activities associated wi…

MaleViral Diseasesmedicine.medical_treatmentEnzyme MetabolismHIV InfectionsParasite loadBiochemistrySeverity of Illness Index0302 clinical medicineBlood plasmaSUPPRESSOR-CELLSMACROPHAGESPLASMA AMINO-ACIDS0303 health sciencesCoinfectionPARASITOLOGYlcsh:Public aspects of medicineImmunosuppression11 Medical And Health SciencesIMMUNODEFICIENCY-VIRUS TYPE-13. Good healthEnzymesSEROPOSITIVE PATIENTSArginaseInfectious DiseasesCoinfectionMedicineLeishmaniasis VisceralBiological MarkersLife Sciences & BiomedicineResearch ArticleNeglected Tropical DiseasesAdultlcsh:Arctic medicine. Tropical medicineAdolescentlcsh:RC955-962030231 tropical medicineINHIBITIONPeripheral blood mononuclear cellMECHANISMS03 medical and health sciencesYoung AdultDONOVANITropical MedicinemedicineParasitic DiseasesACTIVATED GRANULOCYTESHumansAdolescent; Adult; Arginase/blood; Biological Markers/blood; Coinfection/diagnosis; Coinfection/pathology; Cross-Sectional Studies; Ethiopia; HIV Infections/complications; HIV Infections/diagnosis; Humans; Leishmaniasis Visceral/complications; Leishmaniasis Visceral/diagnosis; Male; Severity of Illness Index; Young AdultBiology030304 developmental biologyScience & TechnologyArginasebusiness.industryPublic Health Environmental and Occupational HealthLeishmaniasislcsh:RA1-127006 Biological Sciencesmedicine.diseaseVisceral leishmaniasisCross-Sectional StudiesImmunologyEthiopiabusinessBiomarkersRESPONSES
researchProduct

EARLY EFFICACY OF LIPOSOMAL AMPHOTERICIN B IN THE TREATMENT OF VISCERAL LEISHMANIASIS

1996

The rapidity and efficacy of a short course of liposomal amphotericin B was evaluated in 29 children affected by visceral leishmaniasis (Leishmania infantum). Their overall health status was assessed using the prognostic inflammatory and nutritional index (PINI), and their haematological status by the reticulocyte count and haemoglobin blood levels. All these quantities were measured on day 0, and 3 and 10 d after starting therapy. A significant decrease of inflammatory signs, associated with an improved reticulocyte count, was recorded after 3 d of therapy. A significant increase of haemoglobin levels was also observed 10 d after the start of treatment. The early reduction of inflammatory …

Malemedicine.medical_specialtyAdolescentmedicine.medical_treatmentAntiprotozoal AgentsSeverity of Illness IndexGastroenterologyAmphotericin BAmphotericin BInternal medicineAnimalsHumansMedicineLeishmania infantumChildleishmaniasisDrug CarriersChemotherapybiologybusiness.industryPublic Health Environmental and Occupational HealthInfantAnemiaLeishmaniasisGeneral Medicinebiology.organism_classificationmedicine.diseaseInfectious Diseasesmedicine.anatomical_structureVisceral leishmaniasisItalyChild PreschoolLiposomesImmunologyLeishmaniasis VisceralFemaleParasitologyLiposomal amphotericinHemoglobinBone marrowLeishmania infantumbusinessmedicine.drug
researchProduct

Comparison of N-terminal proB-type natriuretic peptide levels at different stages of visceral leishmaniosis and in patients with chronic kidney disea…

2018

N-terminal proB-type natriuretic peptide (NT-proBNP) may be a useful marker in canine leishmaniosis (CanL). The aim was to compare NT-proBNP in dogs at different LeishVet stages of CanL and with idiopathic chronic kidney disease (CKD). Dogs diagnosed with CanL or CKD and a group of healthy dogs were included (group A, five normal dogs; group B, six dogs LeishVet 1-2; group C, 13 dogs LeishVet 3-4; group D, six dogs with CKD). NT-proBNP was higher (P0.001) in group C (7.616 pmol/l, interquartile range (IQR) 3537-10,000 pmol/l) than in group A (293 pmol/l, IQR 257-373), group B (388.5 pmol/l, IQR 324-793) and group D (740 pmol/l, IQR 557-962 pmol/l). International Renal Interest Society (IRIS…

Malemedicine.medical_specialtyMyocarditisN-Terminal ProB-type Natriuretic Peptide040301 veterinary sciencesmedicine.drug_classLeft ventricular hypertrophyGastroenterologyGroup A0403 veterinary scienceDogsInternal medicineNatriuretic Peptide BrainmedicineNatriuretic peptideAnimalsHumansIn patientcardiovascular diseasesDog DiseasesRenal Insufficiency ChronicGeneral Veterinarybusiness.industry0402 animal and dairy science04 agricultural and veterinary sciencesGeneral Medicinemedicine.disease040201 dairy & animal sciencePeptide FragmentsLeishmaniasis VisceralFemalebusinesshormones hormone substitutes and hormone antagonistsBiomarkersKidney diseaseThe Veterinary record
researchProduct

Visceral obesity and metabolic syndrome: two faces of the same medal?

2009

In this review, we have analyzed the role of visceral obesity in the occurrence of metabolic syndrome (MetS). MetS is a common metabolic disorder that has been related recently to the increasing prevalence of obesity. The disorder is defined in various ways, but in the near future a new definition(s) should be applicable worldwide. The pathophysiology has been largely attributed, in the past years, to insulin resistance, although several epidemiological and pathophysiological data now indicate visceral obesity as a main factor in the occurrence of all the components of MetS. In view of this, relationships among visceral obesity, free fatty acids, dyslipidemia and insulin resistance have bee…

Malemedicine.medical_specialtySettore MED/09 - Medicina InternaAdipokineFatty Acids NonesterifiedBioinformaticsInsulin resistanceAdipokinesInternal medicineEpidemiologyInternal MedicineMedicineHumansDyslipidemiasMetabolic SyndromeAdiponectinbusiness.industryMetabolic disordermedicine.diseaseObesityEndocrinologyObesity AbdominalEmergency MedicineFemaleAdiponectinMetabolic syndromeInsulin ResistancebusinessDyslipidemiaMetabolic syndrome - Visceral obesity - Adipocytokines - AdiponectinInternal and emergency medicine
researchProduct

Clinical and biochemical determinants of the extent of liver steatosis in type 2 diabetes mellitus

2015

Objective Nonalcoholic fatty liver disease is very frequent in both type 2 diabetes mellitus (T2DM) and the metabolic syndrome (MS), which share clinical and metabolic characteristics. Whether and to which extent these characteristics can predict the degree of liver steatosis are not entirely clear. Patients and methods We determined liver fat (divided into four classes) by standard sonographic images, and clinical and biochemical variables, in 60 consecutive patients with T2DM and with features of the MS. We examined both simple and multiple correlations between the degree of liver steatosis and the variables measured. Results Increased liver fat (defined as >5% of liver mass) was detec…

Malenonalcoholic fatty liver diseasemedicine.medical_specialtytype 2 diabetes mellitusmedicine.medical_treatmentSettore MED/50 - Scienze Tecniche Mediche ApplicateGastroenterologyleptinliver steatosispredictive modelInsulin resistanceNon-alcoholic Fatty Liver DiseaseInternal medicineinsulin resistanceNonalcoholic fatty liver diseasemedicineHumansInsulinAdiposityAgedUltrasonographyvisceral adiposityGlycated HemoglobinMetabolic SyndromeSettore SECS-S/06 - Metodi mat. dell'economia e Scienze Attuariali e FinanziarieModels StatisticalAnthropometryHepatologybusiness.industryInsulinHemoglobin A1c; insulin resistance; leptin; liver steatosis; metabolic control; multiple regression analysis; nonalcoholic fatty liver disease; predictive model; type 2 diabetes mellitus; visceral adiposity;GastroenterologyType 2 Diabetes MellitusHemoglobin A1c; insulin resistance; leptin; liver steatosis; metabolic control; multiple regression analysis; nonalcoholic fatty liver disease; predictive model; type 2 diabetes mellitus; visceral adiposity; Gastroenterology; Hepatologymetabolic controlmultiple regression analysisMiddle AgedHepatologymedicine.diseaseEndocrinologyDiabetes Mellitus Type 2Hemoglobin A1cMetabolic control analysisFemaleWaist CircumferenceSteatosisMetabolic syndromebusinesshemoglobin A1c leptin liver steatosis metabolic control multiple regression analysis nonalcoholic fatty liver disease insulin resistance predictive model type 2 diabetes mellitus visceral adiposity
researchProduct